NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
NeuroSense Advances ALS Drug PrimeC, Reducing Protein Linked to 97% of Cases
NeuroSense Therapeutics (NASDAQ: NRSN) met the primary efficacy endpoint in its Phase 2b PARADIGM trial. The study evaluated the ALS drug candidate PrimeC....
🔴 NRSN is trading 5.5% down today after meeting Phase 2b ALS study endpoint
NRSN is trading 5.5% down now at $0.72 after announcing it achieved the primary endpoint in its Phase 2b ALS study, a key milestone for its lead asset...
NeuroSense's Sub-Dollar Stock Gets a Jolt From Alzheimer's Data and Insider Cash — But Can an Eight-Patient Study Justify Real Conviction?
Shares shifted as NeuroSense Therapeutics (NRSN) ticked up 3% to $0.78 ahead of its June 30 Q1 earnings report, capping a string of catalysts: fresh...
🟢 NRSN is trading 3% up today ahead of Q1 earnings and positive clinical updates
NRSN is trading 3% up at $0.78 as investors position ahead of its June 30, 2026, Q1 earnings report and react to positive clinical and financing updates. •...
NeuroSense Therapeutics Ltd Q1 2026 Earnings Preview: What Analysts Expect on June 30, 2026
Analysts expect NeuroSense Therapeutics to report a quarterly loss of $0.14 per share on zero revenue, with the current stock price of $1.42 trailing...
🟢 NRSN up 1.58% today on positive PrimeC Alzheimer's biomarker findings
• NeuroSense Therapeutics (NRSN) is trading up 1.58% today at $0.77 following the announcement of positive biomarker findings from its Phase 2 study of PrimeC...
🟢 Neurosense Therapeutics Ltd is trading 5.6% up today ahead of Q1'26 earnings report
• Neurosense Therapeutics Ltd is trading 5.6% up at $0.85 in pre-market, extending a sharp rebound from recent lows. • The company is expected to announce its...
🟢 Neurosense Therapeutics Ltd is trading 5.7% up today after notable insider buying by top executives
Neurosense Therapeutics Ltd is trading 5.7% up today at $0.74 following significant insider buying by the company's top leadership. • On June 16, 2026, the...
🟢 Neurosense Therapeutics Ltd is trading 5.7% up today amid insider buying by CEO and CFO
• NeuroSense Therapeutics Ltd is trading at $0.74, up 5.7% in pre-market sessions, potentially driven by recent insider buying. • On June 16, 2026, CEO Alon...
🟢 Neurosense Therapeutics Ltd makes sharp 12.1% jump
NRSN is trading at $0.79, up 12.1% versus the comparison close of $0.70 during after-hours. This is a price-movement alert; no separate company-specific...
🟢 Neurosense Therapeutics Ltd. (NRSN) Surges 10% on Insider Buying by CEO and CFO
Neurosense Therapeutics Ltd. (NRSN) traded at $0.77 in after-hours, marking a 10% increase from its regular session close of $0.70. This significant movement...
🔴 Neurosense Therapeutics Ltd is trading 6.2% down today amid low-float volatility and no clear catalyst
Neurosense Therapeutics Ltd is trading 6.2% down at $0.69, extending a choppy micro-cap biotech trend despite a broader market rally. • The move appears...
🟢 Neurosense Therapeutics Ltd is trading 5.3% up today after securing a new patent in South Korea for its ALS drug candidate
Neurosense Therapeutics Ltd is trading 5.3% up at $0.77 in pre-market after the company announced it has been granted a patent in South Korea for its lead ALS...
🔴 Neurosense Therapeutics Ltd is trading 5.1% down today as it consolidates following a recent patent-driven rally
Neurosense Therapeutics Ltd is trading at $0.72 (down 5.1%) as the stock undergoes consolidation following a significant price jump earlier this week. • The...
🟢 Neurosense Therapeutics Ltd is trading 6.6% up today after securing a patent for its ALS candidate PrimeC in Japan
Neurosense Therapeutics Ltd is trading at $0.81 (6.6%) up today, extending momentum from the prior session after the company announced it was granted a patent...
🟢 Neurosense Therapeutics Ltd is trading 5.8% up today after Japan grants patent for ALS drug PrimeC
Neurosense Therapeutics Ltd is trading 5.8% up at $0.80 today after the company announced that Japan has granted a patent for its lead ALS drug candidate,...
🟢 Neurosense Therapeutics Ltd is trading 10.4% up on Japanese Patent Grant for its ALS drug PrimeC
Neurosense Therapeutics Ltd is trading 10.4% up at $0.83 in pre-market action after the company announced a key patent grant in Japan. * The Japan Patent...
🟢 Neurosense Therapeutics Ltd is trading 8% up today in a relief rally following a multi-session slide
Neurosense Therapeutics Ltd is trading 8% up at $0.81 in a relief rally following a multi-session slide and broader risk-off pressure on small-cap biotech...
🔴 Neurosense Therapeutics Ltd is trading 5.1% down today amid broad market sell-off
Neurosense Therapeutics Ltd is trading 5.1% down at $0.74 as a sharp risk-off move in the broader markets pressures small-cap biotech names. • The decline...